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OBJECTIVE—Skeletal muscle insulin resistance is associated
with lipid accumulation, but whether insulin resistance is due to
reduced or enhanced ﬂux of long-chain fatty acids into the
mitochondria is both controversial and unclear. We hypothesized
that skeletal muscle–speciﬁc overexpression of the muscle iso-
form of carnitine palmitoyltransferase 1 (CPT1), the enzyme that
controls the entry of long-chain fatty acyl CoA into mitochondria,
would enhance rates of fatty acid oxidation and improve insulin
action in muscle in high-fat diet insulin-resistant rats.
RESEARCH DESIGN AND METHODS—Rats were fed a stan-
dard (chow) or high-fat diet for 4 weeks. After 3 weeks, in vivo
electrotransfer was used to overexpress the muscle isoform of
CPT1 in the distal hindlimb muscles (tibialis anterior and exten-
sor digitorum longus [EDL]). Skeletal muscle insulin action was
examined in vivo during a hyperinsulinemic-euglycemic clamp.
RESULTS—In vivo electrotransfer produced a physiologically
relevant increase of 20% in enzyme activity; and although the
high-fat diet produced insulin resistance in the sham-treated
muscle, insulin action was improved in the CPT1-overexpressing
muscle. This improvement was associated with a reduction in
triacylglycerol content, the membrane-to-cytosolic ratio of di-
acylglycerol, and protein kinase C  activity. Importantly, over-
expression of CPT1 did not affect markers of mitochondrial
capacity or function, nor did it alter skeletal muscle acylcarnitine
proﬁles irrespective of diet.
CONCLUSIONS—Our data provide clear evidence that a phys-
iological increase in the capacity of long-chain fatty acyl CoA
entry into mitochondria is sufﬁcient to ameliorate lipid-induced
insulin resistance in muscle. Diabetes 58:550–558, 2009
T
he pathogenesis of insulin resistance is a well-
investigated area of research, but the precise
molecular mechanisms that lead to this disorder
are not fully understood. Emerging evidence
suggests that insulin resistance, at least in skeletal muscle,
is caused by dysregulated signaling processes secondary
to lipid accumulation (1–4). Although the increase in lipid
content is manifested as an increase in triacylglycerol
(TAG), it is likely that elevated TAG may only serve as a
marker of dysfunctional muscle fatty acid metabolism and
that accumulation of bioactive lipids such as diacylglyc-
erol (DAG) and/or ceramide is actually responsible for the
insulin resistance (2,3,5). DAG can activate several iso-
forms of protein kinase C (PKC), which can impair insulin
signal transduction via serine phosphorylation of insulin
receptor substrate (IRS)-1 (6,7). Ceramides can cause
insulin resistance by preventing insulin-stimulated Akt
serine phosphorylation and activation and translocation of
Akt to its substrate (8,9). In addition, ceramide initiates
inﬂammatory signaling pathways, leading to the activation
of both c-jun NH2-terminal kinase (JNK) and nuclear
factor B/inducer of  kinase (10), which have been
implicated in the development of insulin resistance
(11–13).
Several factors may contribute to increased lipid depo-
sition in muscle. An increase in fatty acid uptake without
any change in oxidation could lead to cytosolic lipid
accumulation (14). Conversely, an impaired ability to
utilize fat as a fuel source because of reduced activity of
enzymes of oxidative metabolism and fatty acid utilization
could also result in increased cytosolic lipids (15–17).
Recently, the concept of defective fatty acid oxidation
causing insulin resistance has been challenged. Muoio and
colleagues (18) have suggested that the increased ﬂux of
long-chain fatty acids into the mitochondria is not accom-
panied by complete -oxidation because of the inability of
the tricarboxylic acid (TCA) cycle to cope with the in-
crease in the demand on fatty acid metabolism. This leads
to intramitochondrial metabolite accumulation, mitochon-
drial stress, and cellular insulin resistance (18). Thus, the
role of fatty acid oxidation in regulating insulin sensitivity
is controversial and mechanisms remain unresolved. Car-
nitine palmitoyltransferase 1 (CPT1) is a mitochondrial
transmembrane enzyme thought to be rate limiting for
long-chain fatty acid entry into the mitochondria for
-oxidation (16,19). Inhibition of CPT1 with the chemical
etomoxir increases lipid deposition and exacerbates insu-
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(20), whereas overexpression of CPT1 protects myotubes
against lipid-induced insulin resistance (21,22), arguing
that alterations in fatty acid ﬂux into the mitochondria are
critical in regulating lipid effects on insulin sensitivity.
Thus, to test whether increasing the capacity for fatty acid
ﬂux into the mitochondria is, in itself, sufﬁcient to increase
fat oxidation and alter insulin action, we used an approach
in which we selectively overexpressed the muscle isoform
of CPT1 in skeletal muscle in vivo. The results show that
a physiological increase in CPT1 activity is sufﬁcient to
improve insulin resistance caused by a high-fat diet, sug-
gesting that entry of long-chain fatty acids into the mito-
chondria is more critical in the regulation of fatty acid
oxidation than the downstream capacity of the -oxidation
and TCA cycle.
RESEARCH DESIGN AND METHODS
Vector construction. The human CPT1B cDNA was a gift from Dr. Feike van
der Leij (van Hall University of Applied Sciences, Leeuwarden, the Nether-
lands) and was constructed as previously described (23).
Animal maintenance and surgery. Male Wistar rats (200 g; Animal
Resources Centre, Perth, Australia) were acclimatized at 22  0.5°C under a
12-h light/12-h dark cycle for 1 week on a standard chow diet (8% calories from
fat, 21% calories from protein, and 71% calories from carbohydrate; Gordon’s
Specialty Stock Feeds, Yanderra, New South Wales, Australia) with ad libitum
water. Thereafter, one-half of the animals were switched to a high-fat diet
(45% of calories from fat [lard]), 20% calories from protein, and 35% calories
from carbohydrates; 4.7 kcal/g; based on Rodent Diet D12451; Research Diets,
New Brunswick, NJ for 4 weeks. One week before study, the right and left
jugular veins of rats designated to undergo euglycemic-hyperinsulinemic
clamp studies were cannulated as previously described (24). Rats were single
housed and handled daily to minimize stress. Body weight was recorded daily,
and only those rats that had fully recovered their presurgery weight were
subsequently studied. All experimental procedures were approved by the
Garvan Institute/St. Vincent’s Hospital Animal Experimentation Ethics Com-
mittee and were in accordance with the National Health and Medical Research
Council (NHMRC) of Australia Guidelines on Animal Experimentation.
In vivo electrotransfer. The purifed CPT1 plasmid was directly injected into
rat tibialis anterior muscle by a previously described protocol (23,25,26). The
tibialis anterior muscle was chosen because it can be electroporated easily
without the requirement of surgery, and the ﬁber composition is representa-
tive of the entire musculature of the rat. We have previously reported that this
protocol results in a transfection rate of 50% of ﬁbers (25,26). Hyperinsu-
linemic-euyglycemic clamps (subsequently described) were performed on
animals 7 days after transfecting the tissue, a time point when we have shown
peak CPT1 overexpression (23). Because we also observed overexpression in
the extensor digitorum longus (EDL) muscle, which lies in close proximity to
the tibialis anterior muscle, EDL was sampled from a subset of animals 7 days
after electroporation, and glucose uptake and fatty acid oxidation (described
below) were determined. Unless otherwise stated, the muscles were rapidly
freeze-clamped using precooled tongs and stored at 80°C.
PCR and Western blot analysis. The mRNA abundance of genes encoding
the proteins involved in electron transfer/oxidative phosphorylation (ET/
OxPhos), peroxisome proliferator-activated receptor  coactivator-1 (PGC-1
), nuclear respiratory factor-1 (NRF-1), mitochondrial transcription factor A
(tFAM), and protein abundance were analyzed using real-time RT-PCR and
Western blot analysis as previously described (27,28).
CPT1 activity and palmitate metabolism. Mitochondria were isolated
using a previously described protocol (23,29,30). The forward radioisotope
assay for the determination of CPT1 (EC 2.3.1.21) activity was used as
described by McGarry et al. (31) with minor modiﬁcations (23). To examine
palmitate metabolism in control and transfected muscles, the EDL muscle was
carefully dissected into longitudinal strips from tendon to tendon by use of a
27-gauge needle. Strips were removed and assayed as previously described
(23,32).
Glucose uptake and insulin signaling in isolated EDL muscle. Glucose
uptake in isolated EDL muscle strips was assayed in sealed ﬂasks containing
pregassed (95% O2/5% CO2) Krebs-Henseleit bicarbonate buffer, pH 7.4,
supplemented with 2 mmol/l sodium pyruvate, 8 mmol/l mannitol, and 0.1%
wt/vol BSA at 30°C. Muscles were allowed to recover for 30 min and were
incubated without or with insulin (1 mU/ml) for 30 min. Glucose uptake was
assayed for 15 min using [
3H]-2-deoxy-D-glucose (1 mmol/l; 0.128 	Ci/ml) as
described previously (33). For analysis of insulin signaling, isolated EDL
muscles were preincubated for 30 min and were stimulated for 15 min with 1
mU/ml insulin. Muscles were rinsed with ice-cold saline, blotted, and freeze-
clamped for subsequent analysis.
Hyperinsulinemic-euglycemic clamp. Conscious rats were studied after 5–7
h of fasting. Between 0900 and 1000 h, jugular cannulae were either connected
to a sampling line or an infusion line, and after 30–40 min, hyperinsulinemic-
euglycemic clamps commenced (34), incorporating administration of a bolus
injection of 2-deoxy-D-[2,6-
3H]glucose (GE Healthcare Life Sciences, Bucking-
hamshire, U.K.). Insulin was infused at a rate of 0.25 units  kg
1  h
1. After
120 min, rats were killed by intravenous injection of sodium pentobarbital,
and the tibialis anterior muscles were rapidly dissected and freeze-clamped.
The area under the tracer disappearance curve of 2-deoxy-D-[2,6,-
3H]glucose
together with the counts of phosphorylated [
3H]deoxyglucose from individual
muscles were used to calculate the glucose metabolic index (Rg
). During the
clamp procedure, plasma glucose was determined every 10 min.
Subcellular fractionation and PKC analysis and intramuscular lipid
analysis. Tibialis anterior muscle was homogenized in ice-cold buffer con-
taining 20 mmol/l HEPES (pH 7.4), 2 mmol/l EGTA, 50 mmol/l ß-glycerophos-
phate, 1 mmol/l dithiothreitol, 1 mmol/l Na3VO4, 10% glycerol, 3 mmol/l
benzamidine, 10 	mol/l leupeptin, 5 	mol/l pepstatin A, and 1 mmol/l
phenylmethylsulfonylﬂuoride. The homogenate was centrifuged at 92,000  g
for 30 min at 4°C, and the supernatant was collected as the cytosolic fraction.
The pellet was resuspended in ice-cold homogenization buffer to which 1%
NP-40 was added. The resuspended pellet was incubated on ice for 30 min and
was centrifuged at 50,000  g for 60 min at 4°C. The supernatant, representing
the total membrane fraction, was collected, and the protein content of both
fractions determined. Western blotting was performed using antibodies spe-
ciﬁc for PKC,- /,o r-  (Cell Signaling Technology). TAG content was
determined in the tibialis anterior muscles using an enzymatic colorimetric
technique as previously described (23). DAG and ceramide were extracted and
quantiﬁed according to the enzymatic-radiometric methods of Preiss et al.
(35). DAG and ceramide content was also determined in the membrane and
cytosolic fractions obtained from subcellular fractionation (described above)
to examine the intracellular partitioning of these lipids.
Blood analysis. Blood was transferred into tubes containing EDTA and
centrifuged, and the plasma was stored at 80°C for later analysis. Plasma
glucose was determined using an automated glucose analyzer (YSI 2300; YSI,
Yellow Springs, OH). Plasma free fatty acid (FFA) was assessed by an
enzymatic colorimetric method (Wako; Wako Chemicals, Richmond, VA).
Plasma TAG was determined using an enzymatic colorimetric technique
(Triglycerides GPO-PAP; Roche Diagnostics, Indianapolis, IN). Basal insulin
was assessed using a rat/mouse insulin enzyme-linked immunosorbent assay
(Linco, St. Charles, MO), and clamp insulin was assessed using human ELISA
(Mercodia, Uppsala, Sweden).
Acylcarnitine analysis. Muscle acylcarnitines were analyzed according to
the method of van Vlies et al. (36). Muscle (60 mg) was lyophyllized and
powdered before addition of stable isotope internal standards (NeoGen
Cambridge Isotope Laboratory, Andover, MA) in 1 ml 80% acetonitrile. After
sonication and centrifugation, the supernatant was dried under nitrogen, and
the acylcarnitines were converted to their butyl esters with butanolic HCl.
After evaporation of the butanol, the residue was dissolved in 100 	l 50%
acetonitrile, and tandem mass spectrometric analysis was performed (Quattro
LC; Waters, Milford, MA).
Statistics. Data are reported as means  SE. Comparisons between data
from multiple treatment groups were made using factorial ANOVA followed
by Tukey’s post hoc analysis. To speciﬁcally examine differences in insulin
sensitivity and signaling between control and transfected muscles in animals
fed a high-fat diet, data were analyzed with paired t tests. Statistical signiﬁ-
cance was accepted at P 
 0.05.
RESULTS
CPT1 overexpression increases CPT1 activity and
fatty acid oxidation and reduces fatty acid incorpo-
ration into TAG. The physiological characteristics of the
chow and high-fat diet–treated animals are presented in
Table 1. Because the CPT1 antibody cross-reacts with both
mouse and human CPT1, it recognized both the endoge-
nous and electroporated forms of the protein. In vivo
electroporation resulted in CPT1 being expressed above
endogenous levels by 100% in the tibialis anterior and
EDL (Fig. 1A and B; P 
 0.05) of chow animals. CPT1
protein was increased 40% (Fig. 1A; P 
 0.05) in the
tibialis anterior and 30% in the EDL (Fig. 1B; P 
 0.05) in
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creased by the high-fat diet (Fig. 1A and B; P 
 0.05). CPT1
activity was increased by 40% by CPT1 overexpression in
chow animals and 20% in high-fat diet–fed animals (Fig. 1C;
P 
 0.05). Although fatty acid oxidation tended to be
elevated by high-fat diet, the increase was not statistically
signiﬁcant (Fig. 1D;P0.07). Importantly, CPT1 overexpres-
sion increased fatty acid oxidation in EDL muscles obtained
from chow and high-fat diet–fed animals (Fig. 1D; P 
 0.05).
Palmitate incorporation into DAG was unchanged in muscles
that overexpressed CPT1 (chow empty vector 11.7  1.0
nmol/g; chow CPT1 vector 13.4  0.5 nmol/g; high-fat diet
empty vector 11.6  1.8 nmol/g; high-fat diet CPT1 vector
10.3  1.2 nmol/g). However, palmitate incorporation into
TAG was increased with high-fat diet (P 
 0.05) but was
reduced in muscles overexpressing CPT1 to levels compara-
ble with chow animals (Fig. 1E).
TABLE 1
Characteristics of rats fed a chow or high-fat diet for 4 weeks
Chow High fat
Body mass (g) 316  13 340  8
Plasma glucose (mmol/l) 7.1  0.3 7.6  0.3
Plasma insulin (pmol/l) 187  22 285  51*
Plasma FFA (	mol/l) 0.56  0.05 0.74  0.07
Plasma TAG (mmol/l) 0.94  0.03 1.05  0.24
Epididymal fat (g) 0.95  0.12 1.60  0.15*
Subcutaneous fat (g) 1.49  0.14 2.36  0.21*
Glucose infusion rate
(mg  kg
1  min
1) 40.1  2.6 25.4  2.0*
Data are means  SE. *Signiﬁcantly different from chow (P 
 0.05),
n  9–12.
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FIG. 1. CPT1 overexpression increases CPT1 activity and fatty acid oxidation and reduces fatty acid incorporation into TAG. Representative
immunoblots and quantiﬁcation of CPT1 protein expression in tibialis anterior (A), representative immunoblots and quantiﬁcation of CPT1
protein expression in EDL muscle (B), CPT1 activity in isolated mitochondria from tibialis anterior muscles (C), fatty acid oxidation rate in
isolated EDL muscles ex vivo (D), and fatty acid incorporation into TAG in isolated EDL muscles ex vivo (E) from a leg electroporated with an
empty vector (f) or CPT1 vector () in animals placed either on a standard chow diet or high-fat diet for 4 weeks. Data are means  SE; n 
8. *P < 0.05 main effect for CPT1 expression; †P < 0.05 main effect for diet; #P < 0.05 vs. high-fat diet control leg.
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oxidative capacity and mitochondrial function. We
observed a high-fat diet–induced increase in the activity of
-hydroxyacyl-CoA-dehydrogenase (-HAD; Table 2; P 

0.05) and a trend for increased PGC-1 protein expression
in tibialis anterior (supplementary Fig. 1, available in an
online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db08-1078/DC1), results consistent with a
previous study from our group (37). Neither the high-fat
diet nor CPT1 overexpression affected the expression of
the ET/OxPhos genes in tibialis anterior muscles (Table 2).
We also measured the maximal activity of another impor-
tant mitochondrial enzyme, citrate synthase (Table 2), and
the protein abundance of complex I, II, and V proteins in
the ET/OxPhos chain (supplementary Fig. 1) and observed
no signiﬁcant effect of either high-fat diet or CPT1 over-
expression.
To investigate whether increased ﬂux of fatty acid into
the mitochondria would impair -oxidation via changes in
key metabolite levels, we determined the effect of a
high-fat diet and increased CPT1 activity on acylcarnitine
levels and the ratio of fatty acid oxidation to CO2 and acid
soluble metabolites (ASMs) in EDL muscles. Using tandem
mass spectrometry we analyzed several muscle acylcarni-
tine species ranging from C2 to C16. Free carnitine levels
were not altered by diet or CPT1 overexpression (supple-
mentary Fig. 2, available in the online appendix). We
showed that most muscle acylcarnitine species were af-
fected by neither high-fat diet nor CPT1 overexpression.
However, we observed a small increase in C16 acylcarni-
tine in high-fat diet–fed animals (P 
 0.05), a result
consistent with previous observations (18). Importantly,
however, CPT1 overexpression did not exacerbate C16
acylcarnitine levels in high-fat diet–fed rats (Fig. 2A). To
assess whether this small increase in C16 acylcarnitine
levels in high-fat diet–fed rats affected markers of mito-
chondrial metabolic control, we measured fatty acid oxi-
dation to CO2 and ASM fractions, because if fatty acids are
incompletely oxidized, the percentage of oxidation to CO2
should fall, leading to a concomitant increase in the
percentage of fatty acid metabolites in the ASM fraction.
However, we show that neither the high-fat diet nor CPT1
overexpression affected the percentage of fatty acid oxi-
dation in either the ASM or CO2 fraction (Fig. 2B),
although both high-fat diet and CPT1 overexpression
increased the total oxidation of fatty acids by EDL ex vivo
(Fig. 1C).
CPT1 overexpression restores insulin-stimulated
glucose uptake and insulin signaling due to diet-
induced obesity. Insulin increased glucose uptake
(twofold, P 
 0.05), phosphorylation of IRS1 (Tyr
612;
twofold, P 
 0.05) and Akt (Ser
473; 10-fold, P 
 0.05) in
the EDL. CPT1 overexpression had no effect on these
measures in chow-fed animals (supplementary Fig. 3,
available in the online appendix). However, although the
high-fat diet reduced insulin-stimulated glucose uptake in
the control leg by 30%, overexpression of CPT1 in the
EDL of high-fat diet–fed animals increased insulin-stimu-
lated glucose uptake to levels comparable with control
chow-fed animals (Fig. 3A). Whereas the high-fat diet
reduced the phosphorylation of IRS-1 and Akt under
insulin-stimulated conditions (P 
 0.05), CPT1 overex-
pression in the EDL of high-fat diet–fed animals restored
insulin-stimulated phosphorylation of IRS-1 (Fig. 3B) and
TABLE 2
Markers of oxidative metabolism
Chow High fat
Empty
vector
CPT1
vector
Empty
vector
CPT1
vector
Citrate synthase (	mol  min
1  g
1
wet wt) 3.8  0.4 3.7  0.3 4.0  0.6 3.6  0.4
-HAD (	mol  min
1  g
1 wet wt)* 2.3  0.2 2.2  0.4 5.1  0.4 4.7  0.6
PGC1 mRNA 1.0  0.2 1.3  0.7 1.2  0.3 1.1  0.2
NRF-1 mRNA 1.0  0.2 1.6  0.9 1.3  1.0 1.6  0.6
tFAM mRNA 1.0  0.2 1.2  0.8 1.1  0.4 0.7  0.2
Data are means  SE. Values for mRNA expression are expressed relative to the value obtained from the control leg of chow-fed animals
using ribosomal 18S as a housekeeping gene. *Signiﬁcant main effect for diet (P 
 0.05), n  5–7.
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FIG. 2. Muscle acylcarnitine levels and the ratio of fatty acid oxidation
to CO2 and ASMs in overnight fasted animals. Acylcarnitine levels in
tibialis anterior muscle (A) and the ratio of fatty acid oxidation to CO2
and ASMs (B) in EDL muscle from a leg electroporated with an empty
vector or CPT1 vector, in animals placed either on a standard chow diet
or high-fat diet (HFD) for 4 weeks. Data are means  SE; n  8.
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animals.
Lipid handling by muscle and its role in the etiology of
insulin resistance is a process that involves tissue cross-
talk that is highly inﬂuenced by circulatory factors and ﬂux
of fatty acids across the plasma membrane. Therefore, we
examined the effect of CPT1 overexpression on insulin
action in vivo, by conducting hyperinsulinemic-euglycemic
clamps with the infusion of radiolabeled 2-deoxyglucose
to measure glucose uptake (Rg
) in tibialis anterior mus-
cles. The high-fat diet increased fat pad mass and induced
whole-body insulin resistance, as shown by an increase in
basal insulin levels (Table 1) and a reduction in the
glucose infusion rate during the clamp. Fasting plasma
glucose and FFA were not different after high-fat diet
(Table 1). Rg
 was reduced in the tibialis anterior of
high-fat diet–fed animals (32%, P 
 0.05; Fig. 4A), but
overexpression of CPT1 in the tibialis anterior of chow-fed
animals had no effect on Rg
 (supplementary Fig. 4,
available in the online appendix). In contrast, overexpres-
sion of CPT1 in high-fat diet–fed animals prevented the
decrease in Rg
, restoring rates comparable with the
control leg of chow-fed animals (24.3  3.3 vs. 22.2  3.3
	mol  100 g
1  min
1 for chow and high-fat diet,
respectively; Fig. 4A). Consistent with these ﬁndings, the
phosphorylation of Akt (Ser
473) was enhanced in the
tibialis anterior muscles of high-fat diet–fed animals over-
expressing CPT1 (Fig. 4B).
Basal Insulin Insulin Basal
Basal Insulin Insulin Basal
Basal Insulin Insulin Basal
0.0
0.5
1.0
1.5
*
G
l
u
c
o
s
e
 
u
p
t
a
k
e
(
u
m
o
l
/
g
/
h
r
)
0.0
0.5
1.0
1.5
CPT1 vector      -             -            +           +
Insulin                 -             +            -           +
pY IRS-1 612
Total IRS-1
*
p
Y
 
I
R
S
-
1
 
6
1
2
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
0
2
4
6
8
10
12
CPT1 vector       -             -            +           +
Insulin                  -            +             -           +
p-Akt ser473
Total Akt
*
p
-
A
k
t
 
s
e
r
4
7
3
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
A
B
C
FIG. 3. CPT1 overexpression protects against high-fat feeding–induced
decrements in insulin action and signaling in skeletal muscle ex vivo.
Rates of basal and insulin-stimulated 2-deoxyglucose uptake in iso-
lated EDL muscle from a leg electroporated with an empty vector (f)
or CPT1 vector (), in animals placed on a high-fat diet for 4 weeks
(A); representative immunoblots and quantiﬁcation of phosphoryla-
tion of (Tyr
612)/total IRS1 (B); and phosphorylation (Ser
473)/total Akt
(C) in isolated EDL muscle obtained from a leg electroporated with an
empty vector or CPT1 vector, in animals placed on a high fat-diet for 4
weeks and then incubated in the presence (Insulin) or absence (Basal)
of insulin. Dashed line represents the level of insulin-mediated glucose
uptake or phosphorylation observed in the empty vector leg from
chow-fed animals. Data are means  SE; n  7. *P < 0.05 vs. high-fat
diet control leg under insulin-stimulated conditions.
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FIG. 4. CPT1 overexpression protects against high-fat feeding–induced
decrements in insulin action and signaling in skeletal muscle in vivo.
2-Deoxyglucose uptake (Rg)( A) and representative immunoblots and
quantiﬁcation of phosphorylation (Ser
473)/total Akt (B) in tibialis
anterior muscle obtained from a leg electroporated with an empty
vector or CPT1 vector, in animals placed on a high-fat diet for 4 weeks
and then underwent a hyperinsulinemic-euglycemic clamp for 120 min.
Dashed line represents the level of insulin-mediated glucose uptake or
Akt phosphorylation observed in the empty vector leg from chow-fed
animals. Data are means  SE; n  7. †P < 0.05 main effect for diet;
#P < 0.05 vs. high-fat diet control leg.
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duced accumulation of TAG, the membrane to cyto-
solic ratio of DAG, serine phosphorylation of IRS-1,
and activation of PKC and JNK. The high-fat diet
increased TAG, whereas overexpression of CPT1 de-
creased TAG in both chow and high-fat diet conditions
(Fig. 5A). Both DAG and ceramide content in the tibialis
anterior muscle were increased with high-fat diet, but
overexpression of CPT1 affected neither DAG nor cer-
amide content (data not shown). However, the bioactivity
of deleterious lipid species is critically dependent on their
cellular localization. We, therefore, measured the mem-
brane-to-cytosolic ratio of DAG and ceramide. The mem-
brane-to-cytosolic ratio of DAG was reduced in muscles
from high-fat diet–fed animals overexpressing CPT1 (Fig.
5B). In addition, although not statistically signiﬁcant, there
was a trend (P  0.07) for the same to occur in the
membrane-to-cytosolic ratio of ceramide (Fig. 5C).
Given that ceramide and DAG act as second messen-
gers, we next measured a raft of signal transduction
pathways known to affect insulin action. The high-fat diet
increased phosphorylation of IRS-1 (Ser
307; Fig. 6A), the
membrane-to-cytosolic ratio of PKC (Fig. 6B), and the
phosphorylation of JNK (Thr
183/Tyr
185). However, these
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FIG. 5. CPT1 overexpression decreases TAG accumulation and the
membrane-to-cytosolic ratio of DAG in skeletal muscle. TAG content
(A) and the membrane-to-cytosol ratio of DAG (B) and ceramide (C)i n
tibialis anterior muscle obtained from a leg electroporated with an
empty vector (f) or CPT1 vector (), in animals placed either on a
standard chow diet or high-fat diet for 4 weeks. Data are means  SE;
n  5–7. *P < 0.05 main effect for CPT1 expression; †P < 0.05 main
effect for diet; #P < 0.05 vs. high-fat diet control leg.
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FIG. 6. CPT1 overexpression protects against high-fat feeding–induced
decrements in serine phosphorylation of IRS1 and activation of PKC
and JNK in skeletal muscle. Representative immunoblots and quanti-
ﬁcation of phosphorylation (Ser
307)/total IRS1 (A), membrane-to-
cytosol ratio of PKC (B), and phosphorylation (Thr
183/Tyr
185)/total
JNK (C) in tibialis anterior muscle obtained from a leg electroporated
with an empty vector (f) or CPT1 vector (), in animals placed either
on a standard chow diet or high-fat diet for 4 weeks. Data are means 
SE; n  5–7. *P < 0.05 main effect for CPT1 expression; †P < 0.05 main
effect for diet; #P < 0.05 vs. high-fat diet control leg.
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6A–C). There were no effects of either CPT1 overexpres-
sion or high-fat diet on FAT/CD36 expression, the phos-
phorylation status and protein expression of AMPK, ACC,
IkB, and MLK3, and membrane-associated PKC/ or -
(supplementary Fig. 5).
DISCUSSION
Although it has been known for many years that excess
lipid leads to insulin resistance, the precise molecular
mechanisms linking lipid oversupply to defective insulin
action are not fully elucidated. It has been suggested that
enhancing fatty acid ﬂux through the mitochondria in the
absence of a concomitant “metabolic remodeling” of mi-
tochondrial machinery may lead to deleterious effects on
insulin action (38), whereas other studies report that
increasing fatty acid oxidation can ameliorate insulin
resistance by reducing intracellular lipid levels (22,39).
Here, we report that a physiologically relevant increase in
skeletal muscle CPT1 protein expression was sufﬁcient to
increase fatty acid oxidation and to prevent high-fat diet–
induced fatty acid esteriﬁcation into intracellular lipids,
subsequently leading to enhanced muscle insulin sensitiv-
ity in high-fat–fed rats in the absence of major changes in
markers of downstream capacity of the TCA cycle and
ET/OxPhos pathways. The insulin-sensitizing effect of
CPT1 overexpression was associated with a lower mem-
brane-to-cytosolic ratio of DAG and reduced PKC activ-
ity. Furthermore, high-fat diet–induced phosphorylation of
JNK and IRS-1 at Ser
307 was reduced with CPT1 overex-
pression. Hence, using a model that selectively increases
ﬂux of fatty acids into the mitochondria by inducing a
physiological overexpression of the rate-limiting enzyme
for mitochondrial fatty acid ﬂux, we clearly show amelio-
ration of high-fat diet–induced insulin resistance.
Whether increasing fatty acid ﬂux into the mitochondria
reduces or exacerbates insulin resistance is the subject of
considerable debate. Several studies have shown that
increased rates of fatty acid oxidation are associated with
skeletal muscle insulin resistance (40,41). Furthermore,
Muoio and colleagues (18) recently demonstrated that
mice lacking the enzyme malonyl-CoA-decarboxylase
(MCD
/), an enzyme whose action theoretically pro-
motes -oxidation by relieving malonyl-CoA–mediated in-
hibition of CPT1, were protected from high-fat diet–
induced insulin resistance. Together with in vitro data,
these authors concluded that reducing fatty acid oxidation
was beneﬁcial with regard to insulin action. These results
are in contrast with the data reported here in which
increasing fatty acid oxidation alleviated insulin resistance
in muscle of fat-fed rats. There are some important meth-
odological differences that may explain this apparent
anomaly. First, we used 4 weeks of high-fat diet to induce
insulin resistance in rats, whereas Koves et al. (18) per-
formed studies after 12 weeks of high-fat diet in both rats
and mice. Thus, it is possible that differences between
studies may be due to the duration of high-fat diet and the
time of exposure of the muscle to hyperlipidemia. Further-
more, whereas our studies were focused on the tibialis
anterior and EDL muscles, which are predominantly white
muscles, Koves et al. (18) mostly used the gastrocnemius
muscle, which is a mixture of red and white. It is also
important to note that in the previous study, the model
was a whole-body MCD
/ mouse, and the researchers
reported insulin tolerance tests as their measure of insulin
action, which cannot distinguish between insulin action in
different insulin-responsive organs. They also examined
the ability of MCD deletion to protect against the devel-
opment of insulin resistance in fat-fed animals. In contrast,
in our study, we used a technique in which we selectively
overexpressed CPT1 in one hind limb of a rat and then
were able to compare muscles from this hind limb with
those obtained from the sham-treated, contralateral limb
to see whether there were alterations to pre-existing,
high-fat diet–induced insulin resistance. This technique
has many advantages. First, the comparable muscles are
subjected to exactly the same circulatory factors. Second,
we were able to increase the activity of CPT1 in a skeletal
muscle to levels seen with physiological interventions
such as exercise training (29). Of note, we have consis-
tently reported a transfection efﬁciency of 50% in the
tibialis anterior muscle (25,26). We did not determine
transfection efﬁciency of the CPT1 plasmid, but based on
our previous reports (25,26), we expect that 40–50% of
ﬁbers would be overexpressing CPT1. However, given that
CPT1 protein was only increased by 40%, it is possible
that the transfection efﬁciency of CPT1 was lower than in
our previous studies, or it may indicate that CPT1 protein
has a rapid turnover rate when overexpressed. Nonethe-
less, the critical aspect of the study is that we achieved a
physiological increase in CPT1 protein and activity that
functionally translated into enhanced rates of fatty acid
oxidation and, importantly, suppressed fatty acid esteriﬁ-
cation into TAG. Having performed hyperinsulinemic-eu-
glycemic clamps with 2-deoxyglucose tracers, we were
able to demonstrate that CPT1 overexpression improves
insulin action in diet-induced obese models. Our results
are entirely consistent with previous work in vitro, where
it has been reported that a two- to threefold overexpres-
sion of CPT1 in L6 myotubes increased oxidation of the
long-chain fatty acids palmitate and oleate and increased
insulin stimulation of [
14C]glucose incorporation into gly-
cogen by 60% (21,22).
In the present study, high-fat diet–induced insulin resis-
tance was associated with an increase in CPT1 activity and
a trend toward elevated fatty acid oxidative capacity (Fig.
1A–C). This is consistent with previously reported data
showing that rodents can adapt to a high-fat diet to
coordinately increase the ability of skeletal muscle to take
up (14) and utilize (37) fatty acid, this being dominant
energy substrate. This is accompanied by muscle insulin
resistance, which is at ﬁrst glance seemingly paradoxical
considering that we here demonstrate that a further en-
hancing of muscle CPT1 expression and fatty acid oxida-
tion in high-fat diet–fed rats had an insulin-sensitizing
effect. However, the critical difference was in the degree of
fatty acid esteriﬁcation (Fig. 1D). In the empty vector
condition, when animals were placed on high-fat diet, fatty
acid incorporation into TAG was increased compared with
chow-fed rats, despite the concomitant increase in CPT1
activity and a trend toward increased fatty acid oxidation.
This increase in fatty acid esteriﬁcation was associated
with increased lipid deposition in membranes (Fig. 6) and
increases in PKC and JNK activation (Fig. 6), resulting in
impaired insulin signal transduction. These data suggest
that diet-induced obesity results in an enhanced entry of
fat into the mitochondria and subsequent oxidation; how-
ever, this increase is quantitatively less than the increase
in fatty acid entry into the tissue, resulting in a net increase
in cellular lipid storage. In contrast, by increasing CPT1
activity in fat-fed animals, in this case due to ectopic
CPT1 AND MUSCLE INSULIN RESISTANCE
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entry into the mitochondria and subsequent oxidation was
sufﬁcient to match the increased rate of fatty acid uptake
into the tissue, thereby preventing any esteriﬁcation into
TAG and subsequent insulin resistance.
Although the total content of bioactive lipids appears to
play a role in regulating insulin action in muscle, it is also
emerging that the subcellular location of lipids plays a
fundamental role in dictating its downstream targets and
cellular responses (42). Many of the proximal steps in
insulin signaling to GLUT4 translocation occur at or in
close proximity to the plasma membrane (43). Thus, it is
possible that excessive accumulation of lipid species, such
as DAG and ceramide, in cellular membranes may affect
insulin action by interfering with the activation of critical
components of the insulin signaling pathway. Such an
effect may be mediated by DAG and ceramide-induced
displacement of cholesterol in membranes (44), which is
associated with decreased Akt phosphorylation (45). In
the current study, we found that the membrane-to-cytoso-
lic ratio of ceramide was increased in muscle of high-fat–
fed animals, and this was associated with impaired
phosphorylation of Akt. We also observed that there was a
tendency for the ceramide membrane-to-cytosolic ratio to
be reduced in muscles overexpressing CPT1 from fat-fed
rats, an effect that may have contributed to enhanced
insulin-stimulated Akt phosphorylation. In addition, we
also found that the DAG membrane-to-cytosolic ratio was
decreased in muscle from fat-fed animals overexpressing
CPT1.
The molecular mechanisms by which lipids induce
insulin resistance in skeletal muscle remain uncertain.
However, it has been suggested that lipid-induced insulin
resistance in muscle is mediated by activation of a serine
kinase cascade that leads to impaired insulin signaling (7).
We were able to show that the high-fat diet not only
induced translocation of PKC to the membrane but also
increased JNK phosphorylation in muscle, which was
associated with an increase in basal IRS-1 Ser
307 phosphor-
ylation. However, when CPT1 was overexpressed in mus-
cles of high-fat diet–fed rats, there was a signiﬁcant
reduction in the membrane-to-cytosol ratio of PKC and
phosphorylation of JNK. These changes were associated
with a decrease in the phosphorylation status of IRS-1 on
Ser
307. Given that phosphorylation of IRS-1 at Ser
307 can
impair subsequent insulin-stimulated tyrosine phosphory-
lation (46), it is likely that the insulin-sensitizing effect of
CPT1 overexpression is mediated by inhibiting the activa-
tion of serine kinases that interfere with insulin signaling.
It is possible that these changes are related to the ob-
served reduction in membrane DAG and ceramide content
in muscles overexpressing CPT1.
In summary, we have shown that moderate overexpres-
sion of CPT1 is sufﬁcient to increase fatty acid oxidation,
thereby preventing fatty acid esteriﬁcation, subsequently
enhancing muscle insulin sensitivity in high-fat–fed rats.
The insulin-sensitizing effect of CPT1 overexpression was
associated with a reduction in muscle TAG content, al-
though no difference in total DAG and ceramide levels was
detected. However, the membrane-to-cytosolic ratio of
DAG was reduced in muscle overexpressing CPT1, and
this was associated with inhibition of PKC and JNK
activity. Hence, we propose that increasing the capacity
for fatty acid oxidation exerts an insulin-sensitizing effect
in muscle by modulating the content of bioactive lipid
species in membranes, preventing the activation of serine
kinases and thereby relieving inhibition on insulin signal-
ing. In addition, CPT1 overexpression did not have any
major effect on markers of “metabolic remodeling,” such
as changes in the protein expression of several subunits of
the respiratory chain, ET/Ox Phos gene expression, max-
imal activity of key mitochondrial enzymes, and muscle
acylcarnitine content, suggesting that under conditions of
physiological increases in fatty acid ﬂux, pathways down-
stream of fatty acid entry into the mitochondria were not
limiting for complete oxidation of fatty acid to CO2.W e
conclude that CPT1 agonists are a potential therapeutic
target for the treatment of obesity and type 2 diabetes.
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